Evorpacept + Zanidatamab combo Generates Durable Response in Patients with Advanced HER2+ve Breast Cancer and High CD47 Expression May 12, 2026
FDA ODAC didn’t reach a majority vote on camizestrant in combination with a CDK4/6 inhibitor for advanced HR+ve HER2neg breast cancer May 6, 2026
FDA Approves VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer May 6, 2026
Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination in 1L Metastatic Breast Cancer Announced April 28, 2026
Incyclix Bio Raises Additional $5 Million in Series B Financing to Advance Clinical Trial of INX-315 in Patients with CDK4/6 Inhibitor Resistant ER+/HER2- Breast Cancer or CCNE1-Amplified Solid Tumors April 15, 2026
Boston Oncology CGT Holding to license Xuanzhu Biopharmaceutical’s Bireociclib and Dirozalkib April 15, 2026
Neoadjuvant Anbenitamab Meets Primary Endpoint in Ph 3 HER2-Positive Breast Cancer Trial April 7, 2026
OnKure Therapeutics Announces Oversubscribed $150M Private Placement to Advance Two PI3Kα Pan-Mutant Selective Inhibitors in Breast Cancer and Vascular Anomalies April 7, 2026
ENHERTU Followed by THP Approved in China for the Neoadjuvant Treatment of HER2+ve Breast Cancer March 31, 2026
Novartis entered into an agreement with Synnovation Therapeutics to acquire SNV4818 for HR+/HER2- breast cancer and other solid tumor indications March 24, 2026
Ph 3 trial FLAMINGO-01 of GLSI-100 to prevent breast cancer recurrences announced the initiation of new clinical sites in the US March 24, 2026
Ph 1a data of TOS-358 in heavily pretreated patients with PI3Kα-mutant metastatic breast cancer and other solid tumors presented March 24, 2026
Data from Ph 1/2 ReDiscover trial of 400mg BID zovegalisib (RLY-2608) + fulvestrant in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer announced March 24, 2026
Primary endpoint met in Ph 2 study, FOURLIGHT-1, showing a 40% reduction in the risk of disease progression or death with manageable safety profile March 24, 2026
Results from PIK3CA WT Cohort of Ph 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer Published in Journal of Clinical Oncology March 17, 2026
Combo Regimen May Improve Pathologic Complete Response Rate in TNBC in Early Ph 2 INVINCIBLE-4 of INT230-6 March 17, 2026
